Beta interferons and glatiramer acetate for treatment of MS: TA guidance 2018. Issue 3 (22nd August 2018)

• Record Type: Journal Article
• Authors: Gaber, Tarek; Shippen, Clare; Cheng, Lin
• Is Part Of: Progress in neurology and psychiatry. Volume 22:Issue 3(2018)
• Page Start: 4
• Page End: 5
• Publication Date: 2018-08-22
• Subjects: Neurology -- Periodicals; Psychiatry -- Periodicals; Nervous system -- Periodicals; 616.805
• DOI: 10.1002/pnp.504
• Languages: English
• ISSNs: 1367-7543

Abstract

Abstract : A recent NICE technology appraisal has updated the 2002 guidelines on the use of beta interferons and glatiramer for the treatment of multiple sclerosis. Initial draft guidance in December 2017 proposed not recommending the use of glatiramer and other beta interferons apart from interferon beta‐1b (Extavia) as interferon beta‐1a and glatiramer were deemed to be not cost effective. Many clinicians and patients disagreed with that conclusion and NICE has duly agreed to revisit the data, integrating best supportive care measures rather than relying completely on a head‐to‐head comparison with the newer medication options.